DUBLIN--(BUSINESS WIRE)--The "Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The anaplastic lymphoma kinase (ALK) inhibitors market will register a CAGR of about 21% by 2023.
The high prevalence of lung cancer is one of the key factors expected to trigger market growth
The increasing need for treatments coupled with the advances in therapeutics such as targeted therapy is encouraging more and more patients to undergo treatments using ALK inhibitor therapeutics. As a result, owing to the strong incidence rates of the disease and the increasing drug approvals, global ALK inhibitors market will register considerable growth during the forecast period.
Presence of patient assistance programs
Patient assistance programs and reimbursement programs are expected to help with the high-cost regimen of ALK inhibitors to a large extent, which would encourage more patients to avail the treatment, thereby driving the market growth.
Adverse effects associated with therapeutics
Despite being highly efficacious, ALK inhibitors used for treatment NSCLC are associated with a spectrum of side effects. These side effects hinder patient adherence to the treatment, which poses a challenge to market growth.
Competitive Landscape
The market appears to be concentrated. ALK inhibitors have demonstrated efficacy in the oncology indications such as NSCLC, which has been encouraging vendors to extend their application to various other oncology indications through additional clinical trials.
This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.
Key Players
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY TYPE
- Comparison by type
- Second-generation ALK inhibitors - Market size and forecast 2018-2023
- First-generation ALK inhibitors - Market size and forecast 2018-2023
- Third-generation ALK inhibitors - Market size and forecast 2018-2023
- Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- RoW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/qsnck0
